Advanced search
1 file | 338.27 KB

Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease

Author
Organization
Abstract
The pathophysiology of inflammatory bowel disease (IBD) involves the production of diverse lipid mediators, namely eicosanoid, lysophospholipids, and platelet-activating factor, in which phospholipase A(2) (PLA(2)) is the key enzyme. Thus, it has been postulated that control of lipid mediators production by inhibition of PLA(2) would be useful for the treatment of IBD. This hypothesis has been tested in the present study by examining the therapeutic effect of a novel natural probitic Bacillus subtilis PB6 (ATCC- PTA 6737). B. subtilis PB6 is found to secrete surfactins (cyclin lipopeptides) which have anti-bacterial potential. These surfactins inhibit PLA(2), a rate-limiting enzyme involved in the arachidonic acid associated inflammatory pathway and could downregulate the inflammatory response by regulating the eicosanoid and cytokine pathways. With this concept, an experimental animal trial has been conducted in a rat model of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The oral administration of PB6 suppresses the colitis as measured by mortality rate, changes in the weight gain, colon morphology and the levels of plasma cytokines. The animals treated orally with PB6 at 1.5 x 10(8) CFU/kg thrice daily from day 4 to 10 significantly improve gross pathology of the colon and regain the colon weight to normal (p<0.05), compared to TNBS-induced positive control. The plasma levels of pro-inflammatory cytokines (TNR-alpha, IL-1 beta, IL-6 and IFN-gamma) are also significantly lowered (p<0.05) and anti-inflammatory cytokine (IL-10 and TGF-beta) significantly (p<0.05) increased after the oral administration of PB6 on day 11. The present study supports the concept that PB6 inhibits PLA(2) by the secreting surfactins. In a clinical investigation it is found to be well tolerated by all the healthy volunteers.
Keywords
Bacillus subtilis PB6, Inflammatory bowel disease, TNBS-induced colitis, Wistar rats, Cytokines, ACTIVATED PROTEIN-KINASE, TUMOR-NECROSIS-FACTOR, LACTIC-ACID BACTERIA, INDUCED COLITIS, LACTOBACILLUS STRAINS, CELLS, MURINE, MICE, INHIBITOR, MODEL

Downloads

  • Selvam 2009 IJBB 46 1 79.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 338.27 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Selvam, R, P Maheswari, P Kavitha, M Ravichandran, Benedikt Sas, and CN Ramchand. 2009. “Effect of Bacillus Subtilis PB6, a Natural Probiotic on Colon Mucosal Inflammation and Plasma Cytokines Levels in Inflammatory Bowel Disease.” Indian Journal of Biochemistry & Biophysic 46 (1): 79–85.
APA
Selvam, R., Maheswari, P., Kavitha, P., Ravichandran, M., Sas, B., & Ramchand, C. (2009). Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease. INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC, 46(1), 79–85.
Vancouver
1.
Selvam R, Maheswari P, Kavitha P, Ravichandran M, Sas B, Ramchand C. Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease. INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC. 2009;46(1):79–85.
MLA
Selvam, R, P Maheswari, P Kavitha, et al. “Effect of Bacillus Subtilis PB6, a Natural Probiotic on Colon Mucosal Inflammation and Plasma Cytokines Levels in Inflammatory Bowel Disease.” INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC 46.1 (2009): 79–85. Print.
@article{627192,
  abstract     = {The pathophysiology of inflammatory bowel disease (IBD) involves the production of diverse lipid mediators, namely eicosanoid, lysophospholipids, and platelet-activating factor, in which phospholipase A(2) (PLA(2)) is the key enzyme. Thus, it has been postulated that control of lipid mediators production by inhibition of PLA(2) would be useful for the treatment of IBD. This hypothesis has been tested in the present study by examining the therapeutic effect of a novel natural probitic Bacillus subtilis PB6 (ATCC- PTA 6737). B. subtilis PB6 is found to secrete surfactins (cyclin lipopeptides) which have anti-bacterial potential. These surfactins inhibit PLA(2), a rate-limiting enzyme involved in the arachidonic acid associated inflammatory pathway and could downregulate the inflammatory response by regulating the eicosanoid and cytokine pathways. With this concept, an experimental animal trial has been conducted in a rat model of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The oral administration of PB6 suppresses the colitis as measured by mortality rate, changes in the weight gain, colon morphology and the levels of plasma cytokines. The animals treated orally with PB6 at 1.5 x 10(8) CFU/kg thrice daily from day 4 to 10 significantly improve gross pathology of the colon and regain the colon weight to normal (p{\textlangle}0.05), compared to TNBS-induced positive control. The plasma levels of pro-inflammatory cytokines (TNR-alpha, IL-1 beta, IL-6 and IFN-gamma) are also significantly lowered (p{\textlangle}0.05) and anti-inflammatory cytokine (IL-10 and TGF-beta) significantly (p{\textlangle}0.05) increased after the oral administration of PB6 on day 11. The present study supports the concept that PB6 inhibits PLA(2) by the secreting surfactins. In a clinical investigation it is found to be well tolerated by all the healthy volunteers.},
  author       = {Selvam, R and Maheswari, P and Kavitha, P and Ravichandran, M and Sas, Benedikt and Ramchand, CN},
  issn         = {0301-1208},
  journal      = {INDIAN JOURNAL OF BIOCHEMISTRY \& BIOPHYSIC},
  keyword      = {Bacillus subtilis PB6,Inflammatory bowel disease,TNBS-induced colitis,Wistar rats,Cytokines,ACTIVATED PROTEIN-KINASE,TUMOR-NECROSIS-FACTOR,LACTIC-ACID BACTERIA,INDUCED COLITIS,LACTOBACILLUS STRAINS,CELLS,MURINE,MICE,INHIBITOR,MODEL},
  language     = {eng},
  number       = {1},
  pages        = {79--85},
  title        = {Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease},
  url          = {http://nopr.niscair.res.in/bitstream/123456789/3339/1/IJBB\%2046(1)\%2079-85.pdf},
  volume       = {46},
  year         = {2009},
}

Web of Science
Times cited: